NEW YORK (GenomeWeb) – Investigators from the University of Pennsylvania Health System's Center for Personalized Diagnostics have compared tumor profiling by next-generation sequencing with single-gene tests and found that the results agreed most of the time, suggesting that NGS is a reliable platform for routine clinical use.
In total, UPenn CPD has now sequenced over 5,500 tumor samples, according to Jennifer Morrissette, the center's clinical director.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
